About Valence Life Sciences
Valence Life Sciences is a venture capital firm founded in 2012. It is primarily based out of New York City, United States. As of May 2020, Valence Life Sciences has invested in 13 companies. It primarily invests in Series C round in United States based startups. Its investments are spread across Life Sciences and Enterprise Applications sectors. Most recently it participated in the $***** Series C round of CalciMedica Overall, Valence Life Sciences portfolio has seen 7 IPOs and 6 acquisitions including key companies like CalciMedica, Atea and Vivus. A lot of funds co-invest with Valence Life Sciences, with names like Mesa Verde Venture Partners sharing a substantial percentage of its portfolio. Valence Life Sciences has team of 2 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series C & Series D
Portfolio IPOs
Valence Life Sciences' List of Top Investments
Valence Life Sciences has a portfolio of 13 companies. Their most notable investments are in Invuity and CalciMedica.Their portfolio spans across United States and Italy. They have invested in Life Sciences, Enterprise Applications, across Series C, Series D stages. Here is the list of top investments by Valence Life Sciences:1. CalciMedica
Developer of CRAC channel inhibitor drugs for inflammatory diseases. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications.
Key facts about CalciMedica
- Founded Year: 2006
- Location: San Diego (United States)
- Stage: Public
- Total Funding till date: $76.7M
- Employee Count: 17 as on Sep 30, 2026
- Investors: Aisling Capital, Bering Capital and 11 Others
- Latest Funding Round: Venture Debt, Apr 06, 2025, $*****
- Highlight: Public
_1579497693661.png?format=webp&height=120&width=120){kind=logo}
2. Atea
Developer of therapeutics for viral diseases. It helps users in the treatment of infections caused by RNA and DNA viruses. It also gives solutions for various diseases like Hepatitis C, Dengue, Respiratory Syncytial Virus (RSV), Hepatitis B, and many more.
Key facts about Atea
- Founded Year: 2014
- Location: Boston (United States)
- Stage: Public
- Total Funding till date: $293M
- Employee Count: 58 as on Sep 30, 2026
- Investors: HTIF, Bain Capital Life Sciences and 18 Others
- Latest Funding Round: Post IPO, Jun 13, 2023, $*****
- Highlight: Public
3. Vivus
Vivus is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. It has developed a Tacrolimus lead pipeline program that helps to treat pulmonary arterial hypertension (PAH).
Key facts about Vivus
- Founded Year: 1991
- Location: Mountain View (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2019
- Stage: Public
- Employee Count: 184 as on Sep 30, 2026
- Investors: Colt Ventures, Athyrium Capital Management and 9 Others
- Latest Funding Round: Post IPO, May 2013, $*****
- Highlight: Public
Developing targeted and immuno-oncology therapeutics for cancer patients. Focused on advancing cancer treatment through innovative therapies, the company develops humanized monoclonal antibodies. Their pipeline includes programs targeting proteins like DKK1 and GDF-15, with clinical candidates in development for esophagogastric, gynecologic, and colorectal cancers. They are dedicated to understanding tumor expression and creating new targets and combinations. The company is committed to stopping cancer through new therapies. They are working towards expanded access for patients. The company is involved in research and development, clinical trials, and regulatory affairs.
Key facts about Leap Therapeutics
- Founded Year: 2011
- Location: Cambridge (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2021
- Stage: Public
- Total Funding till date: $24.7M
- Employee Count: 18 as on Sep 30, 2026
- Investors: Perceptive Advisors, Bering Capital and 6 Others
- Latest Funding Round: Post IPO, Oct 06, 2025, $*****
- Highlight: Public
5. Invuity
Invuity develops products using advanced photonics for direct visualization of surgical cavities during minimally invasive procedures. The products use a proprietary optical waveguide technology for illumination of the surgical target. Its stated application areas include orthopedic, spine, breast and thyroid surgeries. The company went public in June 2015.
Key facts about Invuity
- Founded Year: 2004
- Location: San Francisco (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2017
- Stage: Acquired
- Total Funding till date: $92.3M
- Employee Count: 50 - 199 as on Mar 01, 2026
- Investors: Bering Capital, Wellington and 14 Others
- Latest Funding Round: Post IPO, Mar 2018, $*****
- Highlight: Acquired
Valence Life Sciences' Year-on-Year Investment Trends
Valence Life Sciences has invested in 13 companies over the last 14 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in CalciMedica and most recent follow-on round was in Invuity.Valence Life Sciences' Investments by Stage
Valence Life Sciences has made 1 investment in Series C stage with an average round size of $17.2M and 1 investment in Series D stage with an average round size of $25M.Valence Life Sciences' Investments by Sector
Valence Life Sciences has a portfolio focused on Life Sciences. Notably, it has invested in 12 Tech companies, 7 Enterprise (B2B) companies, 4 Software companies and at least 1 company focusing on Consumer (B2C).Valence Life Sciences' Investments by Geography
Valence Life Sciences has made most investments in United States (2).Valence Life Sciences' recent investments
Valence Life Sciences has not made any investment in 2026 so far.Here are the most recent investments by Valence Life Sciences:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 26, 2020 | United States | Series C | 2111 | ||
Feb 06, 2015 | United States | Series F | 2230 | [+4] | |
Mar 04, 2014 | United States | Series E | 6799 | ||
Jun 12, 2012 | United States | Series D | 2962 | [+2] |
IPOs and Publicly Listed companies in Valence Life Sciences' Portfolio
7 of Valence Life Sciences' portfolio companies have become public. Atea got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2020 and CalciMedica got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Valence Life Sciences' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 30, 2020 | - | - | 4410 | |
Sep 25, 2020 | May 26, 2020 | Series C | 7118 | |
Jan 24, 2017 | - | - | 6337 | |
Aug 22, 2013 | - | - | 9650 | |
Mar 01, 2010 | - | - | 9277 |
_1579497693661.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Acquired companies in Valence Life Sciences' Portfolio
6 companies from Valence Life Sciences' portfolio have been acquired. The most recent acquisition was ArQule in Dec 2019 by Merck for $*****.Here are Valence Life Sciences' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 09, 2019 | - | - | 2152 | |
Sep 11, 2018 | Jun 12, 2012 | Series D | 5826 | |
Jul 01, 2014 | - | - | 5718 | |
Dec 19, 2013 | - | - | 1950 | |
Mar 21, 2011 | - | - | 9892 |
Team profile of Valence Life Sciences
Valence Life Sciences has a team of 2 members located in United States. Valence Life Sciences' team does not sit on the board of any company as of now.Co-investors of Valence Life Sciences
Over the past 14 years, 15 investors have co-invested in Valence Life Sciences's portfolio companies. This includes funds and angels.
- Invested before Valence Life Sciences: Sanderling Ventures, SR One and 4 others have invested in rounds before Valence Life Sciences. There is 1 company where Sanderling Ventures has invested before Valence Life Sciences and 1 company where SR One has invested before Valence Life Sciences.
- Top Co-investors of Valence Life Sciences: 3 investors entered a company along with Valence Life Sciences. These include investors like Mesa Verde Venture Partners (1 company).
- Invested after Valence Life Sciences: A total of 6 investors have invested in Valence Life Sciences's portfolio after their investments. Top Investors include Avenue Capital Group (1 company), HealthCare Royalty Partners (1 company) and Windham Venture Partners (1 company).
Recent News related to Valence Life Sciences
•
CalciMedica Raises $15M in Series C FinancingFinSMEs•May 25, 2020•CalciMedica, Valence Life Sciences, Bearing Capital, Mesa Verde Venture Partners and 3 others
•
Invuity Secures $36M in Series E Financing |FinSMEsFinSMEs•Mar 04, 2014•Invuity, HealthCare Royalty Partners, InterWest Partners, Valence Life Sciences and 2 others
•
Invuity® Raises $36 Million in Series E Financing | Business WireBusiness Wire•Mar 04, 2014•Invuity, HealthCare Royalty Partners, InterWest Partners, Valence Life Sciences and 2 others
•
Celator Pharmaceuticals Inks $32.5M in New Funding - PE HubPE Hub•May 01, 2013•Valence Life Sciences
•
Invuity Raises $25 Million in Series D Funding - InvuityInvuity•Jun 14, 2012•Invuity, InterWest Partners, Wexford Capital, Valence Life Sciences and 1 other
•
Invuity® Raises $20 Million Funding RoundPR Newswire•Invuity, Wellington, HealthCare Royalty Partners, InterWest Partners and 2 others
